235 results about "Synovitis" patented technology

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and / or a synovitis biomarker.

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and / or a synovitis biomarker.

The instant invention provides a method of treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, the reduction or inhibition of the production of Hyaluronic acid, said method comprising orally administering to a mammalian species a therapeutically effective amount of Hyaluronic Acid or pharmaceutically acceptable salts thereof. Additionally, compositions containing hyaluronic acid; chondroitin sulfate, and glucosamine sulfate in a paste formulation are also disclosed which can be administered on their own or can be used as a feed additive.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

This invention relates to treating, preventing, and lessening the severity of conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors.

The invention relates to a temperature-sensitive in-situ gel preparation composition for intra-articular injection and a preparation method thereof, and belongs to the field of medicine preparations. The preparation method comprises the following steps: preparing diclofenac sodium-carrying sodium alginate microspheres by combining a microsphere technology with a temperature-sensitive gel technology, and then carrying the medicine-carrying microspheres in a chitosan / beta-sodium glycerophosphate temperature-sensitive in-situ gel system to obtain a diclofenac sodium in-situ gel preparation composition. The composition is in a liquid state at a room temperature, capable of being converted to a semi-solid gel at a body temperature and forming a medicine storeroom at a medication part after being partially injected to enter an articular cavity, and beneficial to slowly releasing the medicine, prolonging the time of staying at the injection part, of the medicine, and enhancing the efficacy. The composition disclosed by the invention can be used for treating arthritis diseases of rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and the like, as well as applicable to both diclofenac sodium and other arthritis treatment medicines of non-steroidal anti-inflammatory medicines, steroid hormone medicines, biological preparations and the like.

The present invention provides an intra-articular injection administration preparation containing trehalose, which is characterized in that the preparation contains the trehalose. The present invention can improve the capabilities of the cartilage cells to adapt to and resistant to the environmental changes through the intra-articular injection administration, at the same time, the trehalose has the significant effects of antioxidant and anti-free radicals, which can alleviate the symptoms of arthritis; in addition, the trehalose also provides the necessary sugar for cartilage repair, so as to repair and reconstruct the cartilage. The present invention is used for improving and treating the rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and / or cartilage injury.

The invention provides a xanthan-gum-containing pharmaceutical preparation for joint intracavity injection, which is characterized by containing xanthan gum. In the preparation, xanthan gum used as a pharmaceutical component for joint cavity injection has the advantages of favorable viscoelasticity and favorable lubricating property, has particular thixotropy, can be used as an excellent pharmaceutical release-control carrier, and can act in the joint cavity for a long time. The pharmaceutical preparation can improve and treat rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and / or cartilage injury, and effectively relieve pain of patients.

The invention relates to a medicament for treating arthralgia and myalgia. The medicament is prepare from the components in parts by weight as follows: 1000 parts of nux vomica, 100 parts of radix clematidis, 100 parts of caulis sinomenii, 100 parts of garden balsam stem, 100 parts of lycopodium clavatum, 100 parts of berba aristolochiae mollissimae, 100 parts of monkshood, 100 parts of radix aconiti agrestis, 100 parts of the root of red-rooted salvia, 100 parts of angelica sinensis, 100 parts of rheum officinale, 100 parts of dragon's blood, 100 parts of semen momordicae, 100 parts of eucommia ulmoides, 100 parts of cinnamon, 100 parts of radix angelicae pubescentis, 100 parts of notopterygium root, 100 parts of asarum, 100 parts of radix achyranthis bidentatae, 100 parts of homalomena occulta, 100 parts of anisetree bark, 100 parts of radices sileris, 100 parts of caper, 100 parts of monkshood, 100 parts of ligusticum wallichii, 100 parts of Chinese polyphaga, 100 parts of scorpio, 100 parts of centipede, 100 parts of frankincense, 100 parts of myrrh, 100 parts of leech, 60 parts of camphor, 60 parts of borneol, 20 parts of musk and 300 parts of zaocys dhumnade. The medicament provided by the invention can be used for treating cervical spondylosis, brain swelling cervical pain, scapulohumeral periarthritis, scapula back pain, pelvospondylitis, thoracic vertebra pain, elbow joint pain, pain in waist and lower extremities, lumbar disc herniation, cervical and lumbar spinal stenosis, osteoproliferation, ischiadic nerve pain, knee-joint dropsy, synovitis, knee pain and rheumatic arthritis.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The invention relates to novel AMPK agonist containing compositions that are adapted for localised use in treating inflammation and / or pain due to disease or injury in a human or animal. The novel compositions of the invention are useful in the treatment of a variety of conditions including osteoarthritis (OA), synovitis, tendonitis, desmitis; cystitis, osteitis and laminitis. Routes of administration include intra-articular, direct injection into tissues, instillation, retrograde perfusion and topical. AMPK agonists which can be used include AICAR, metformin, phenformin, A-769662, resveratrol, berberine and polyphenols.

The invention discloses medicinal oil for acupuncture and a preparation method as well as application thereof to preparing medicaments for treating headache, cervical vertebra or lumbar vertebra hyperostosis, knee joint synovitis, gout, rheumatoid arthritis, chronic enteritis, diarrhea and scrofula. According to the invention, optimized improvement is made on the basis of an ancient prescription of Zhuang people; cassia twig, agilawood, elecampane, safflower, angelica, root of bidentate achyranthes, szechuan lovage rhizome and muskiness are used as raw materials; and the medicinal oil which is used during acupuncture treatment has the characteristics of quick response, clear curative effect and high cure rate for diseases such as headache, cervical vertebra or lumbar vertebra hyperostosis, knee joint synovitis, gout, rheumatoid arthritis, chronic enteritis, diarrhea and scrofula, can be specifically used for curing difficult diseases such as cervical vertebra or lumbar vertebra hyperostosis, protrusion of intervertebral disc and rheumatoid arthritis which are difficult to cure by normal acupuncture and modern medicine, and has extremely high medical value and social significance.

The invention relates to a traditional Chinese medicine external patch for treating rheumatism and rheumatoid diseases. In traditional Chinese medical science, limb pain or numbness caused by wind, cold and humidity is considered as rheumatism, and the rheumatism is mainly caused by the wind, the cold and the humidity that enter human bodies in weak states, flow and fill in channels and collaterals and joints to obstruct the qi and blood operation. The rheumatoid diseases are arthropathy on the basis of synovitis resulted from autoimmune response caused by infectious diseases. The traditional Chinese medicine external patch comprises the follow ingredients in parts by weight: 1 to 5 parts of radix aconiti kusenzoffii, 1 to 5 parts of unprocessed radix aconiti kusnezoffii, 1 to 5 parts of ma-huang, 1 to 5 parts of aconite, 1 to 5 parts of cinnamon, 1 to 5 parts of rhizoma zingiberis, 1 to 5 parts of frankincense, 1 to 5 parts of myrrh, 1 to 4 parts of asarum and 14 parts of rhizoma arisaematis. The traditional Chinese medicine external patch is applied to the treatment of the rheumatism and the rheumatoid diseases.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method. Said cartilage product is useful in the treatment or prevention of wounds, ulcers, burns, psoriasis, osteoarthritis, synovitis, osteoporosis, osteopenia, diseases of the tendons and ligaments, periodontal diseases, signs of skin aging, the harmful effects of ultraviolet radiation exposure or stretch marks.

The invention discloses a synovitis treating medicine and a preparation method thereof. The medicine is prepared from the following traditional Chinese medicines in parts by weight: 12.0-14.0 parts of spica prunellae, 8.7-9.5 parts of rhizoma smilacis glabrae, 8.7-9.5 parts of tetrandra root, 13.0-13.8 parts of semen coicis, 6.3-7.1 parts of radix salviae miltiorrhizae, 4.1-4.9 parts of Chinese angelica and 6.5-7.3 parts of herba siegesbeckiae. The invention also provides the preparation method of the medicine, which comprises the steps of decocting, filtering and concentrating to obtain a thick paste, and adding conventional accessories into the thick paste to obtain the medicine in a clinically acceptable form. The synovitis treating medicine disclosed by the invention has good anti-inflammation and analgesic effects.

The invention discloses a combined drug for treating synovitis, including an oral drug and an external application drug. The part rate of the oral drug is that Rhizoma Atractylodis 10-20 parts, Cortex Phellodendri 10-20 parts, Radix Stephaniae Tetrandrae 10-20 parts, Chaenomeles sinensis 10-20 parts, Harms Manyprickle Acanthopanax 10-20 parts, Radix Clematidis Chinensis 10-20 parts, Radix Angelicae Pubescentis 10-20 parts, Radix Paeoniae Alba 10-20 parts, Radix Astragali 30-60 parts, Semen Coicis 30-60 parts, Radix Codonopsis 30-60 parts, Radix Angelicae Dahuricae 8-15 parts and Ramulus Cinnamomi 8-15 parts. The part rate of the external application drug is that Radix Aconiti Kusnezoffii 2-20 parts, Radix Aconiti, 5-10 parts, Rhizoma et Radix Notopterygii 5-20 parts, Flos Carthami 5-10 parts, Radix Saposhnikoviae 10-20 parts, Ramulus Cinnamomi 5-10 parts, Ramulus Mori 2-5 parts, Rhizoma Atractylodis 5-10 parts, Radix Aconiti Lateralis Preparata 10-20 parts, Herba Epimedii 5-10 parts, Caulis Impatientis 10-20 parts, Radix Angelicae Pubescentis 10-20 parts, Radix Angelicae Dahuricae 10-20 parts and Herba Asari 10-20 parts. The combined drug of the invention achieves the potency of drug to be directly delivered to the focus through oral taking, local suffocating and foment and realizes good treatment effect.

The instant invention provides a method and composition for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, said method comprising administering effective amounts of Boswellia Serrata, effective amounts of freeze dried green lipped mussle, effective amounts of white willow bark extract containing salicin, effective amounts of angelica root, effective amounts of glucosamine and salts thereof, effective amounts of chondroitin and salts thereof and effective amounts of omega 3 fatty acids.

The invention provides an ELISA kit for detecting avian onfectious synovitis antibody. The kit adopts the ELISA kit for detecting the avian onfectious synovitis antibody, based on avian onfectious synovitis pyruvate kinase (PYK) recombinant protein as envelope antigen. The invention further provides a preparation method of the envelope antigen of the kit, namely PYK protein. The PYK protein prepared through the method has excellent reactogenicity, and the ELISA detection kit provides an effective method for the diagnosis of avian onfectious synovitis and the detection of an antibody level after immunization, and has an obvious promotion effect on the prevention research on avian onfectious synovitis.

The invention discloses an external tincture for treating bone poliomyelitis and a preparation method of the external tincture. The external tincture comprises the following ingredients in parts by weight: 18-24 parts of radix aconiti, 18-24 parts of peach kernel, 18-24 parts of radix aconiti carmichaeli, 15-22 parts of dried tangerine or orange peel, 10-18 parts of folium artemisiae argyi, 18-25 parts of radix clematidis, 25-30 parts of semen brassicae, 10-15 parts of tuberculate speranskia herb, 10-20 parts of safflower carthamus, and 0.5-1.5 parts of musk. The external tincture in reasonable in compatibility of medicines, can treat various bone poliomyelitis effectively, such as cervical spondylopathy, scapulohumeral periarthritis, pain in waist and lower extremities, traumatic injury, sciatica, rheumatic arthritis, rheumatoid arthritis, hyperostosis, spinal stenosis, tenosynovitis, synovitis, gout, years of old injury, lumbar disc herniation, osteonecrosis of the femeral head, swelling, limp and numb, pain and the like caused by qi-stagnancy and blood stasis and blockage of meridians, is simple in formula, is good in osmotic effect, and is remarkable in treatment effect.

The invention discloses a drug composition for treating synovitis and a preparation method of the drug composition. The drug composition is prepared by taking herbs of smalllfower seaberry, roots of Denseflower Euonymus, ziyuglycoside II, Concolorous Doryoteris and roots of P. tibetanicum Wolff as crude drugs and proportioning, can be prepared into various dosage forms according to a conventional preparation technology and is remarkable in curative effect on treating the synovitis.

The invention relates to a medicament for treating arthromeningitis, which comprises Mongolian milkvetch root, atractylodes rhizome, coixseed, indian buead and honeysuckle flower and is prepared by the steps of: adding 5000ml of water into the Mongolian milkvetch root, the atractylodes rhizome, the coixseed and the indian buead, decocting until 500ml liquid left, then adding the honeysuckle flower, and decocting until 250ml liquid left. The medicine is bound to be taken before sleeping every night, and generally, a disease can be cured after 2-3 doses of the medicaments are taken. The medicament can achieve the purpose of curing by promoting profuse sweating, inducing diuresis and excreting dampness, as well as removing toxic materials and subsiding swelling so as to expel the disease through sweating, and can be used for treating the arthromeningitis with fast effect-taking, good curative effect and total effective rate reaching 98.3 percent.

The invention discloses a preparation for treating synovitis and a preparation method thereof. The preparation for treating synovitis is prepared from the following components in percentage by weight:0.4%-1% of meloxicam, 20%-60% of phospholipid, 20%-60% of glyceride, 1%-15% of non-ionic surfactant and 1%-20% of cosolvent. The preparation for treating synovitis provided by the invention has goodstability, the meloxicam serving as an effective component can be slowly released lastingly in the human body, the human body can lastingly absorb the medicine for a long time, and the medicine can act in the human body for a long time, so that the treatment effect is better and the bioavailability of the medicine is higher.

This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.

The invention provides an identification method of a traditional Chinese medicine preparation for treating synovitis. The traditional Chinese medicine preparation is of granules prepared from 11 traditional Chinese medicines including radix astragali, radix gentianae macrophyllae, radix angelicae sinensis, radix dipsaci, cortex moutan, radix bupleuri, rhizoma curcumae longae, herba taxilli, rhizoma dioscoreae septemlobae, radix cyathulae and liquorice root. According to the identification method provided by the invention, an existing identification method is improved, an identification methodof the radix bupleuri, the radix dipsaci and the radix angelicae sinensis is improved and an identification method of the radix astragali seu hedysari, the radix gentianae macrophyllae and the radix cyathulae is increased; the identification of the rhizoma curcumae longae is deleted; an operation method is simple and color spectrum spots are clear; the identification method is negative and has nointerference, has strong specificity and good repeatability, can control the quality of a product better and has good application value.

The invention relates to a formula for treating and preventing arthritis, synovitis and other orthopaedic diseases and complicating diseases and discloses a main compound extracted from mangosteen:Garcinia mangostana. In the main compound, alpha-mangostin serving as a main ingredient is used in combination with various common filters in pharmaceuticals industry to prepare various proper formulations including tablets, capsules, powders, suppositories and the like for oral or external use for treating and preventing arthritis diseases such as rheumatoid arthritis, chronic infectious arthritis, post-traumatic arthritis, osteoarthritis and purulent arthritis as well as complicating diseases of the arthritis diseases such as inflammations of finger joints, metacarpophalangeal joints, wrist joints, elbow joints, shoulder joints, knee joints, spondyl joints, ankle joints, metatarsophalangeal joints and other joints. The alpha-mangostin content of the product of the invention is between 0.1 and 99.9 percent. The product manufactured by the formula can relieve the various inflammations and has certain analgesic effect. The product can be used alone or in combination with other substances.